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The inadequacies of conventional immunosuppression with 
azathioprine and Prednisone have been serious enough to prevent the 
full exploitation of organ transplantation procedures. The prospect 
of improving the situation was dependent on new immunosuppression 
techn i ques. In 1976, Borel, et a 1 (1,2) descri bed the i rnmunodepres-
sive properties in mice, rats, and guinea pigs of an extract from the 
fungi Cylindrocarpon lucidum and Trichoderma polysporurn. This agent, 
Cyclosporin A, suppressed cellular and hurnoral immunity without bone 
marrow depression or other prohibitive organ toxicity. 
Clinical trials were begun in 1978 by Calne, et al (3,4,5) of 
Cambridge, England with encouraging results. In late 1979, Cyclo-
sporin became available for preliminary testing in the United States 
(11). We report here our experience with this drug in two institu-
tions, and with three organs (the kidney, liver and heart). Much of 
this information has been published in detail elsewhere (7,8,9,11). 
METHODS OF IMMUNOSUPPRESSION 
In the first part of the experience with kidneys and livers, 
Prednisone was withheld postoperatively until there were manifesta-
tions of rejection. When it became obvious that rejection occurred 
in more than half of the cases, treatment was standardized as 
follows: 
On the day of (or the day before) operation and after, Cyclo-
sporin A was given at a dose of 17.5 mq/kg/day. This was continued 
daily for two months if possible. Often, this dose was decreased at 
the end of that time (or before in the event of toxic side effects) 
to the 10 mg/kg/day range. In adults, Prednisone was started at a 
dose of 200 mg on the day of operation with decreases of 40 mgrn for 
the next four days. On day five, the dose was reduced from 40 to 
20 mg. After this, weaning from the 20 mg/day was on the basis of 
the clinical course. Deviations from this plan were made if dictated 
by postoperative complications including the supervention of rejec-
tion. Rejections were treated with a one gram bolus of hydrocorti-
sone plus a five day course of high dose oral Prednisone as described 
above. In small adults or children, steroid therapy was appropri-
ately adjusted. 
* Supported by Grants. 
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For hepatic and cardiac recipients, treatment was made more 
flexible according to the clinical state of the patients. For 
extremely ill liver recipients, early Prednisone therapy was scaled 
down. For heart recipients, the daily decrements from the high of 
200 mg/day were by 20 instead of 40 mg/day. 
The matches of the recipients with their donors were poor. 
The number of mismatches at the HLA-A and B loci averaged more than 
three. At the DR locus, there were no perfect matches in the recip-
ients for whom this information was available. The sera of all 
recipients were analyzed for antibody content. Many of the graft 
recipients had warm anti-T or anti-B-lymphocyte antibodies against 
more than 20% of a lymphocyte panel obtained from healthy volunteers. 
Two of the liver and one of the heart recipients had transplantation 
against donor specific T-warm antibodies which cause hyperacute 
rejection of kidneys. The heart recipient had a stormy course, 
during which biopsies showed deposition of complement and immuno-
globulins in the vessels. Under intensive therapy with hydrocorti-
sone, she recovered and biopsy evidence of humoral rejection receded. 
The liver recipients were not adversely effected by the preformed 
antibody state. One A liver was transplanted to a B blood type 
recipient with no adverse effect. 
RESULTS IN COLORADO EXPERIENCE 
Renal Transplantation 
Sixty-six patients were given 67 renal homografts, includ-ing 
nine recipients who were undergoing retransplantation. No attempt 
was made to deliberately transfuse the recipients in advance of 
operation. Many of them were referred from Nephrology centers in 
which transfusion had been avoided. 
Nine patients (13.6%) died from 20 to 335 days after trans-
plantation. Of these nine, five had good or excellent function at 
the time of death. Two of the deaths were in elderly patients who 
died of coronary artery disease, and a third patient died of a stroke. 
These deaths were not related to immunosuppression. Six patients 
died of opportunistic infections (invariably pulmonary) and these 
recipients were considered to have been over immunosuppressed. 
Follow-up is 11 to 21 months for the 57 patients still living. 
Fifty (75.8%) of the original 66 patients are free of dialysis. 
The serum creatinine concentrations in the 50 patients still 
bearing kidneys is summarized below. All of these recipients having 
satisfactory and stable function, but as previously reported by Calne 
et al (4), a nUlllber of patients with clinically good results have 
slightly abnormal renal function. 
TABLE 1. PRESENT GRAFT FUNCTION IN LIFE-SUSTAINING KIDNEYS 
SERUM CREATININE 
< 1.5 mg% 
1.6 - 2.5 mg% 
2.6 - 3.5 mg% 
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After 4 to 1P~ months, Cyclosporin A was stopped in 6 patients. 
In each instance, nephrotoxicity was suspected. Nithin 13 days to 
10 weeks, two of the recipients rejected their kidneys. The other 
four have had stable or improved renal function in the ensuing 11, 
10, 7 and 4 months. 
Twelve kidneys became available for study 14 to 335 days after 
transplantation. In seven, immunosuppression had been stopped for a 
significant period previously and six of these grafts showed evidence 
of rejection. In four it was acute, superimposed in one instance 
upon chronic rejection, in one it was chronic, and in another acute 
rejection was just commencing. The seventh kidney was normal 11 days 
after stopping immunosuppression, except for a few fibrin thrombi in 
glomerular capillaries and in arterioles. 
Five kidneys came from patients who had received continuous 
immunosuppression. Two of these showed changes of chronic rejection, 
in one there was mild cellular infiltration, and in the fourth there 
was no evidence of rejection. The fifth kidney in a patient with 
oxalosis was crammed with oxalate crystals. There was no rejection. 
An unusual feature in three of the seven grafts which showed 
signs of acute rejection was the presence of eosinophils in the 
interstitial cellular infiltrate. One graft showed patchy acute 
tubular necrosis, but there was no morphological evidence of a 
specific Cyclosporin induced tubular lesion. 
The results of kidney survival have been analyzed according to 
primary cadaveric versus retransplantation (9). After 11 to 21 
months, the results are as follows: 
Primary Cadaveric Transplantation - Of the 57 kidneys trans-
planted into 57 recipients, nine were placed in recipients who died 
(see above) and three more were lost to rejection, two before and one 
after one year. One kidney failed after 10 months because of 
recurrent oxalosis. Thus, 44 (77.2%) of the 57 grafts are supporting 
life. The one year graft survival of 78% is superior to that ever 
achieved by us with other techniques of immunosuppression, including 
thoracic duct drainage (in combination with azathioprine and Predni-
sone). 
Cadaveric Retrans lantation - Of ten kidneys transplanted into 
nine reclpients, 6 SM~ are unctioning after 1S~I 16, 14, 13, 12 
and 10 months. Three organs were lost to rejection. The fourth was 
removed because of complete ureteral necrosis, after which retrans-
plantation was carried out successfully. 
Liver Transplantation 
Between March and September, 1980, 14 patients, ages 8 to 41 
years were accepted for the pilot trial of liver transplantation 
under Cyclosporin A. Two patients who were scheduled to be treated 
with Cyclosporin A plus Prednisone died during operation. One bled 
to death from a portal vein laceration and the other received a homo-
graft too large to permit the abdomen to be closed. Thus, only 12 
patients were treated with immunosuppression. 
The general techniques of liver replacement were as previously 
described (6,10). Seven of the 14 livers were removed in cities 
other than Denver (75 to 2000 miles away). All 14 livers were 
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preserved with Collins solution. Ischemia times were 11" to 10"2 hours. 
Biliary tract reconstruction was by duct to duct, gall bladder to jejunal Roux limb, and common duct to Roux limb anastomosis, in that 
order of frequency. Two patients required secondary operations to 
relieve bile duct obstruction. 
Of the 12 patients who survived operation, three had chronic 
aggressive hepatitis and three had Budd-Chiari Syndrome. There was 
one example each of primary biliary cirrhosis, sclerosing cholangitis 
(associated with cholangiocarcinoma), hepatoma, Byler's disease, and 
intrahepatic atresia. The two patients who died during operation 
had sclerosing cholangitis and secondary biliary cirrhosis (previous 
gun shot wound to the hepatic hilum). 
Among the 12 patients who survived operation and who could be 
treated with immunosuppression, the only postoperative death was of a 
child 19 days after transplantation. The hepatic artery of the homo-
graft had thrombosed. 
Two patients died late, one at 12 and the other after 15 months. 
The first death was due to recurrent cholangiocarcinoma which had 
been in the excised native liver. The second late death was due to 
recurrent Budd-Chiari Syndrome. 
Nine (75%) of the 12 patients are alive after follow-ups of 10 
to 17 months. All but one have normal liver functions, and all are 
living at home. 
Seven of the nine survivors are beyond one year. Including the 
two patients who died after one year, the actuarial one year survival 
projection of patients who could be treated with Cyclosporin is 11 of 
12 (91.8%). Even including the two patients who died intraoperative-
ly, the one year survival is projected at 78.6%. These results are 
superior to any in our past experience (6,8,10). 
Many liver biopsies were obtained, invariably because of post-
operative liver function abnormalities. These biopsies revealed a 
variety of findings of which the most common was acute cellular 
rejection. Rejection was always responsive to increased steroid 
therapy. 
RESULTS IN PITTSBURGH EXPERIENCE 
Further experience with Cyclosporin A has been acquired at the 
University of Pittsburgh in renal, hepatic, and cardiac recipients 
for whom follow-ups are available of two weeks to 4"2 months. 




























Thus far, the only loss of a primary or secondary kidney graft 
was from technical error (one renal vein and one renal artery throm-
bosis). Four of the kidney grafts are viable by radionuclide flow 
scan, but not functioning well. 
The first four liver recirients died. Common to all the 
failures was poor initial function of the grafts which was thought to 
be due to ischemic injury during procurement and preservation. The 
next six recipients have done well. 
The four heart recipients are well, including the one whose 
serum had donor specific preformed T-warm cytotoxic antibodies. 
MORBIDITY FROM IMMUNOSUPPRESSION 
The infections in the first renal recipients were due to over-
immunosuppression with steroids in an imprudent effort to salvage 
kidneys. The pneumonidites were caused by Pneumocystis carinii, 
nocardia, or were of undetermined etiology. One patient had a lung 
abscess which was treated with left lower lobectomy after immuno-
suppression was stopped. A number of patients had Herpes simplex at 
some time. There were no examples of Herpes Zoster. Miscellaneous 
infections included histoplasmosis, and amebic colitis. 
The well being of patients treated with Cyclosporin A was 
remarkable, mainly because of the low doses of Prednisone which 
usually were in effect by the end of five days. Hirsutism, gum 
hyperplasia, flushing and paresthesias after drug ingestion, and 
tremors were minor annoyances. 
One renal recipient died of pulmonary emboli and pneumocystis 
pneumonia 110 days after transplantation. At autopsy, an incidental 
finding was small nodular deposits of a B-cell immunoblastic sarcoma 
in the retroperitoneal and para-aortic lymph nodes, in the spleen, in 
the liver and in the heart. Much of the tumor was necrotic. Immuno-
peroxidase techniques revealed that the tumor was monoclonal, many 
of the cells producing mu heavy chains and kappa light chains. The 
origin of the tumor could not be determined because host and donor 
were of the same sex. 
Another renal recipient had a mid-small bowel perforation 157 
days after transplantation. She had a segmental intestinal resection 
and remains well more than a year later. Her Cyclosporin dose was 
reduced from 15.8 to 5.9 mg/kg/day. In the base of the perforated 
ulcer were nests of lymphoid cells. Determination of intracellular 
immunoglobulins by immunoperoxidase techniques indicated that these 
cells were polyclonal, 95% of the cells producing alpha and 5% gamma 
heavy chains. The kappa light chain to lambda light chain ratio was 
6:1. The cells showed female chromatin markers, i.e., they were of 
host orgin because the donor was male. The eventual diagnosis in the 
concensus opinion of a number of pathologists was that the lesion was 
a lymphoproliferative reaction, not a lymphoma. 
In both patients, the stored sera before and after renal trans-
plantation were examined for antibodies against Epstein-Barr virus. 
In both cases the antivirus capsidantigen titer rose significantly 
after renal transplantation. In the second patient, this was the 
result of a primary infection. The patient with a lymphoma had 
antibody before transplantation suggesting reactivation of EB virus. 
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Neither patient showed increased antibody production to cytomegalo-
virus or Herpes simplex virus (9). 
DISCUSSION 
Thus far, the clinical trials with Cyclosporin A have escaped 
the disillusionment of other promising developments in immunosuppres-
sion. However, they have raised questions about the optimal use of 
this agent, which will have to be taken into consideration by those 
planning randomized trials. The most persistent of the questions has 
been whether to use Cyclosporin A as the sole immunosuppressive 
therapy as practiced by Calne et al (3,4,5), or to combine it from 
the beginning with Prednisone as we have recommended (7,8,9,11). 
Because the survival of heart and liver recipients is synonymous with 
graft survival, the omission of steroid therapy in such patients 
would be hard to justify. In renal recipients whose viability can be 
maintained by hemodialysis, studies using Cyclosporin A alone are 
still justified. 
SIH:cessful use of Cyclosporin in transplantation of human homo-
grafts has depended upon a thorough understanding of the drug's 
toxicity. Injury to the kidney and liver were monitored in all organ 
recipients with a view to dose reduction when indicated. The toxic 
properties of Cyclosporin A were not serious enough to prevent its 
chronic use. Most of the other side effects of Cyclosporin A have 
not been serious, including gum hyperplasia, tremor, and regional 
flushing or vague abdominal discomfort just after drug ingestion. 
The most publicized question about Cyclosporin has concerned 
its potential oncogenicity. It has been known for 15 years that the 
price of effective conventional immunosuppression is an increased 
incidence of de novo tumors of which approximately 1/3 are lymphomas. 
We have seen only one lymphoma in our experience with 123 patients 
treated with Cyclosporin. To our knowledge no epithelial tumors have 
been seen in any center. As experience with Cyclosporin A has 
accumulated worldwide, the specter of this drug being a spectacular 
tumor producer has receded. 
CONCLUSION 
Unless some other, as yet unrecognized, side effect emerges to 
limit the usefulness of Cyclosporin A, this agent should permit 
significant advances in whole organ transplantation. The early 
results in our preliminary trials have been better than in any of our 
previous series of renal, hepatic, and heart transplantations in our 
institutions, in spite of the inclusion of many recipients who were 
at higher than average risk. Cyclosporin A will be particularly 
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